TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of VX-770 on Lung Clearance Index in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 >90% Predicted
Brief Summary: The purpose of this study is to evaluate the effect of ivacaftor (VX-770) on lung clearance index (LCI) in subjects aged 6 years and older with cystic fibrosis (CF) who have the G551D-CFTR mutation on at least 1 allele.


Options:
A: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor
B: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo | Arm Label: Treatment Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carbetocin at Elective Cesarean Delivery: A Dose Finding Study
Brief Summary: Post-partum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the most commonly uterotonic drug used to prevent and treat PPH in North America, however, there are some limitations to its use. Oxytocin has a very short duration of action, which requires a continuous infusion to achieve sustained uterotonic activity. The Society of Obstetricians and Gynecologists of Canada (SOGC) has recently recommended a single 100mcg dose of carbetocin at elective Cesarean delivery to promote uterine contraction and prevent post partum hemorrhage (PPH), in lieu of the more traditional oxytocin regimens. Carbetocin lasts 4 to 7 times longer than oxytocin, with a similar side effect profile and apparent greater efficacy rate. However, a dose response to determine the minimum effective dose of carbetocin has not yet been published.

We hypothesize that a dose-response study will establish the minimum dose of carbetocin required to produce appropriate contractility in 95% of the women (ED95) undergoing elective cesarean delivery.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic Acid
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin infusion | Intervention Type: DRUG; Name: Oxytocin infusion; Assigned to Arm(s): A
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: UnijectTM; Type: EXPERIMENTAL; Interventions: Device: UnijectTM | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DEVICE; Name: UnijectTM; Assigned to Arm(s): UnijectTM
D: Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 90mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 110mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 90mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 110mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 120mcg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carbetocin at Elective Cesarean Delivery: A Dose Finding Study
Brief Summary: Post-partum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the most commonly uterotonic drug used to prevent and treat PPH in North America, however, there are some limitations to its use. Oxytocin has a very short duration of action, which requires a continuous infusion to achieve sustained uterotonic activity. The Society of Obstetricians and Gynecologists of Canada (SOGC) has recently recommended a single 100mcg dose of carbetocin at elective Cesarean delivery to promote uterine contraction and prevent post partum hemorrhage (PPH), in lieu of the more traditional oxytocin regimens. Carbetocin lasts 4 to 7 times longer than oxytocin, with a similar side effect profile and apparent greater efficacy rate. However, a dose response to determine the minimum effective dose of carbetocin has not yet been published.

We hypothesize that a dose-response study will establish the minimum dose of carbetocin required to produce appropriate contractility in 95% of the women (ED95) undergoing elective cesarean delivery.


Options:
A: Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 90mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 110mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 90mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 110mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 120mcg
B: Arm Label: TXA; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
D: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin, oxytocin2, oxytocin3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study: Lactoferrin for Prevention of Neonatal Sepsis
Brief Summary: We will test the hypothesis that bovine lactoferrin supplementation prevents serious infections in preterm infants. We will conduct a randomized placebo-controlled double blind study in 190 premature infants \<2500 gm in 5 Neonatal Intermediate and Intensive Care Units in Lima, Peru to determine whether bovine lactoferrin prevents the first episode of late-onset sepsis.


Options:
A: Arm Label: Bovine Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Bovine Lactoferrin | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bovine Lactoferrin; Assigned to Arm(s): Bovine Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
B: Arm Label: Lactoferrin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: lactoferrin | Arm Label: maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: lactoferrin; Assigned to Arm(s): Lactoferrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): maltodextrin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Talactoferrin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Talactoferrin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: bovine lactoferrin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo [maltodextrin] | Intervention Type: DIETARY_SUPPLEMENT; Name: bovine lactoferrin; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo [maltodextrin]; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Diabetes Care for Korean American Immigrants
Brief Summary: The primary aims are to test the effectiveness of the self-help DM intervention (SHIP-DM), a comprehensive, culturally tailored DM management intervention, in improving glucose outcomes; To determine the effectiveness of the SHIP-DM in KAI with type 2 DM in improving self-care skills and psycho-behavioral outcomes related to DM control, to develop tangible infrastructures for the dissemination of valid and effective education materials to a wider population of KAI with type 2 DM in the US (e.g., audio-visual education materials, web-based intervention materials, mobile telephone-based intervention materials) and to explore the feasibility and acceptability of each dissemination module, utilizing the delayed intervention group participants. The secondary aims are to obtain preliminary cost-effectiveness data related to the proposed intervention, including cost estimates for this type of DM intervention, and to establish a systematic, long-term dissemination plan, including documenting effective methodologies, to facilitate faster translation of research findings and products to direct consumers in non-research settings.


Options:
A: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling
B: Arm Label: STRIP intervention; Type: EXPERIMENTAL; Interventions: Other: STRIP intervention | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: STRIP intervention; Assigned to Arm(s): STRIP intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Comprehensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes, Drug: Antiplatelet Agents, Drug: Beta Blocker, Drug: ACE Inhibitors | Arm Label: Less Intensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes | Intervention Type: BEHAVIORAL; Name: Lifestyle Changes; Assigned to Arm(s): Comprehensive Intervention Group, Less Intensive Intervention Group | Intervention Type: DRUG; Name: Antiplatelet Agents; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: Beta Blocker; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: ACE Inhibitors; Assigned to Arm(s): Comprehensive Intervention Group
D: Intervention Type: PROCEDURE; Name: Therapeutic education; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Diabetes Care for Korean American Immigrants
Brief Summary: The primary aims are to test the effectiveness of the self-help DM intervention (SHIP-DM), a comprehensive, culturally tailored DM management intervention, in improving glucose outcomes; To determine the effectiveness of the SHIP-DM in KAI with type 2 DM in improving self-care skills and psycho-behavioral outcomes related to DM control, to develop tangible infrastructures for the dissemination of valid and effective education materials to a wider population of KAI with type 2 DM in the US (e.g., audio-visual education materials, web-based intervention materials, mobile telephone-based intervention materials) and to explore the feasibility and acceptability of each dissemination module, utilizing the delayed intervention group participants. The secondary aims are to obtain preliminary cost-effectiveness data related to the proposed intervention, including cost estimates for this type of DM intervention, and to establish a systematic, long-term dissemination plan, including documenting effective methodologies, to facilitate faster translation of research findings and products to direct consumers in non-research settings.


Options:
A: Arm Label: online mutual management; Type: EXPERIMENTAL; Interventions: Device: Welltang App | Arm Label: online self-management; Type: EXPERIMENTAL; Interventions: Device: Welltang App | Arm Label: hospital regular management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Welltang App; Assigned to Arm(s): online mutual management, online self-management
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Peer counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Assigned a peer counselor | Arm Label: Financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentives | Intervention Type: BEHAVIORAL; Name: Assigned a peer counselor; Assigned to Arm(s): Peer counseling | Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): Financial incentives
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diabetes Peer Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Peer Counseling | Intervention Type: BEHAVIORAL; Name: Diabetes Peer Counseling; Assigned to Arm(s): Diabetes Peer Counseling
D: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Diabetes Care for Korean American Immigrants
Brief Summary: The primary aims are to test the effectiveness of the self-help DM intervention (SHIP-DM), a comprehensive, culturally tailored DM management intervention, in improving glucose outcomes; To determine the effectiveness of the SHIP-DM in KAI with type 2 DM in improving self-care skills and psycho-behavioral outcomes related to DM control, to develop tangible infrastructures for the dissemination of valid and effective education materials to a wider population of KAI with type 2 DM in the US (e.g., audio-visual education materials, web-based intervention materials, mobile telephone-based intervention materials) and to explore the feasibility and acceptability of each dissemination module, utilizing the delayed intervention group participants. The secondary aims are to obtain preliminary cost-effectiveness data related to the proposed intervention, including cost estimates for this type of DM intervention, and to establish a systematic, long-term dissemination plan, including documenting effective methodologies, to facilitate faster translation of research findings and products to direct consumers in non-research settings.


Options:
A: Arm Label: IIDEA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Integrated Intervention for Dual Problems and Early Action | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Intervention for Dual Problems and Early Action; Assigned to Arm(s): IIDEA
B: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling
C: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity Information (DVD); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DVD | Arm Label: High Intensity Information (Promotora); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Promotora | Intervention Type: BEHAVIORAL; Name: DVD; Assigned to Arm(s): Low Intensity Information (DVD) | Intervention Type: BEHAVIORAL; Name: Promotora; Assigned to Arm(s): High Intensity Information (Promotora)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial of Oral Health Promotion Interventions Among Patients Following Stroke
Brief Summary: The main aim of this oral health intervention project is to compare the effect of providing 1) professional oral hygiene instruction alone versus 2) professional oral hygiene instruction plus adjunctive Chlorhexidine mouth rinse versus 3) professional oral hygiene instruction plus adjunctive assisted tooth brushing and Chlorhexidine mouth rinse, on the oral health condition, the general health condition and health-related quality of life (HRQoL) of patients with stroke who are receiving hospital-based rehabilitation. An additional aim is to assess potential longer term oral intervention-related health and HRQoL outcomes.


Options:
A: Arm Label: OHI; Type: EXPERIMENTAL; Interventions: Other: Oral hygiene intervention | Arm Label: OHI + CHX mouthrinse; Type: EXPERIMENTAL; Interventions: Other: Oral hygiene intervention | Arm Label: OHI + CHX mouthrinse + assisted brushing; Type: EXPERIMENTAL; Interventions: Other: Oral hygiene intervention | Intervention Type: OTHER; Name: Oral hygiene intervention; Assigned to Arm(s): OHI, OHI + CHX mouthrinse, OHI + CHX mouthrinse + assisted brushing
B: Arm Label: Enhanced complex oral health care intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced complex oral health care | Arm Label: Usual oral health care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced complex oral health care; Assigned to Arm(s): Enhanced complex oral health care intervention
C: Arm Label: enhanced oral care; Type: EXPERIMENTAL; Interventions: Other: Enhanced Oral Care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual oral care | Intervention Type: OTHER; Name: Enhanced Oral Care; Assigned to Arm(s): enhanced oral care | Intervention Type: OTHER; Name: Usual oral care; Assigned to Arm(s): Usual care
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Oral screen | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oral screen; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
Brief Summary: Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by changes in the nonalcoholic fatty liver disease (NAFLD) activity score (NAS).


Options:
A: Arm Label: Metformin, Adiponectine, Arterial Compliance; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin, Adiponectine, Arterial Compliance
B: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: high dose; Type: EXPERIMENTAL; Interventions: Drug: Aramchol | Arm Label: low dose; Type: EXPERIMENTAL; Interventions: Drug: Aramchol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aramchol; Assigned to Arm(s): low dose | Intervention Type: DRUG; Name: Aramchol; Assigned to Arm(s): high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Obeticholic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: obeticholic acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: obeticholic acid; Assigned to Arm(s): Obeticholic acid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D